Detalles de la búsqueda
1.
Inhibition of Phosphodiesterase 12 results in Antiviral Activity against several RNA Viruses including SARS-CoV-2.
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-509178
2.
Strong correlations between the binding antibodies against wild type and neutralizing antibodies against omicron BA.1 and BA.2 variants of SARS-CoV-2 in individuals following booster (third dose) vaccination
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22276959
3.
Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22276016
4.
Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3 to 4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22282735
5.
Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine.
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22271735
6.
Neutralizing Activities against the Omicron Variant after a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22269986
7.
Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-426463
8.
Genome-first detection of emerging resistance to novel therapeutic agents for SARS-CoV-2
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-500063
9.
Neutralization of SARS-CoV-2 by destruction of the prefusion Spike
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-079202
10.
The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 B.1.351 and other variants of concern in preclinical studies.
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-447308
11.
Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20091694
12.
Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21267534
13.
Neutralising antibodies to SARS coronavirus 2 in Scottish blood donors - a pilot study of the value of serology to determine population exposure
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20060467
14.
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-148387
15.
Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-492554
16.
SARS-CoV-2 RNA detected in blood samples from patients with COVID-19 is not associated with infectious virus
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20105486
17.
Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-435194
18.
Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients.
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-134551
19.
Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21256571
20.
A haemagglutination test for rapid detection of antibodies to SARS-CoV-2
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20205831